Developer docs
API playgroundTry for free, no card

Search company profiles

Renaissance Pharma

Full company profile

uuid000ms9u

Namestring
Renaissance Pharma
Legal namestring
Renaissance Pharma Ltd
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Renaissance Pharma Ltd is a clinical-stage pharmaceutical company developing Daretabart (hu14.18K322A), a humanised anti-GD2 monoclonal antibody immunotherapy for the treatment of high-risk neuroblastoma (HRNB), a rare paediatric cancer with only a 50% five-year survival rate under current multimodal standard of care. Founded in 2023 in Manchester, UK by Executive Chairman Lee Morley and CEO Simon Ball, the company in-licensed Daretabart exclusively from St. Jude Children's Research Hospital in August 2023, securing development, manufacturing and commercialisation rights across the US, Canada, Europe, China, Japan and Turkey.

The technical core is a humanised anti-GD2 antibody engineered with three differentiating features: 98% human composition, a specialised cell line producing lower antibody glycosylation, and a K322A mutation designed to limit complement activation and improve tolerability versus earlier-generation anti-GD2 antibodies. Phase II clinical data demonstrated an 86.0% overall survival rate at three years and a 73.7% event-free survival rate in newly diagnosed HRNB patients, with 96.8% achieving partial response or better at the end of induction. In April 2026, the FDA granted Fast Track Designation and IND clearance, enabling initiation of the SHINE Phase II/III trial, and the first commercial-scale GMP batch was successfully manufactured.

Renaissance Pharma is pre-revenue; the disclosed revenue model is pharmaceutical product sales of Daretabart upon regulatory approval. The company was acquired in March 2024 by Essential Pharma, an international specialty pharma group focused on niche, clinically differentiated products, and now operates as a wholly owned subsidiary. Leadership comprises CEO Simon Ball (also Interim CEO of Essential Pharma), Executive Chairman Lee Morley, CMO Dr. Jonathan Morgan and CTO Debra Nevin, with engagement of FDA, EMA and other regulators to configure the optimal submission and commercialisation path.

Short descriptiontext

Renaissance Pharma is a clinical-stage pharmaceutical company developing Daretabart, a humanised anti-GD2 monoclonal antibody immunotherapy for high-risk neuroblastoma in paediatric patients, operating as a wholly owned subsidiary of Essential Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersManchester, United Kingdom
HQ citystring
Manchester
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pediatric oncology therapeutics, monoclonal antibody immunotherapy, rare disease drug development, anti-GD2 antibody treatment, neuroblastoma clinical development
Industry4 codes
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Pediatric Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Pre-revenue development stage company. Revenue will be generated through commercialization of Daretabart (hu14.18K322A) upon regulatory approval for the treatment of high-risk neuroblastoma.

renaissancepharma.co.uk
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Renaissance Pharma is a clinical-stage pharmaceutical company developing Daretabart (hu14.18K322A), a humanized anti-GD2 monoclonal antibody immunotherapy for the treatment of high-risk neuroblastoma in pediatric patients. The investigational compound is being evaluated in the SHINE Phase II/III trial and has received FDA Fast Track Designation and IND clearance. The asset was in-licensed from St. Jude Children's Research Hospital.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase II trial: 86.0% overall survival rate at 3 years, 73.7% event-free survival rate at 3 years
+2 more records
Product overview1 text field

Renaissance Pharma Limited is a single-product pharmaceutical company focused on rare pediatric diseases, specifically high-risk neuroblastoma. The company's sole offering is Daretabart (hu14.18K322A), a humanized anti-GD2 antibody immunotherapy. This investigational compound is the company's lead and only product candidate, currently in clinical development with Phase II data showing 86% overall survival rate at three years. The company operates as a subsidiary of Essential Pharma following acquisition in April 2024.

Product and service1 record
1Daretabart (hu14.18K322A)
CategoryPediatric oncology immunotherapy (investigational biologic)
Description

Investigational humanized anti-GD2 monoclonal antibody immunotherapy engineered to target and destroy high-risk neuroblastoma (HRNB) cells. Specifications: 98% human composition, specialized cell line production with lower glycosylation, and a K322A mutation limiting complement activation. Phase I and II trials demonstrated tolerability and clinical activity in HRNB. In-licensed from St. Jude Children's Research Hospital.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOthersAnnounced on2024-03-22
Description

Essential Pharma, an international specialty pharma group focused on ensuring patients have sustainable access to niche pharmaceutical products, completed acquisition of the entire issued share capital of Renaissance Pharma Ltd on March 22, 2024. This acquisition added a clinical development-stage asset to Essential Pharma's rare disease portfolio. Simon Ball, CEO and co-founder of Renaissance Pharma, continues to work with Essential Pharma on Daretabart development.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-08-01
Description

Exclusive license agreement signed August 1, 2023 for Daretabart (hu14.18K322A). Renaissance Pharma secured exclusive development, manufacturing and commercialisation rights to US, Canada, Europe, China, Japan and Turkey. The antibody was originally developed by St. Jude and targets GD2 on neuroblastoma cells.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Atreca
TypeEmerging player
Description

Atreca is a clinical-stage biotechnology company leveraging its immune repertoire capture technology to develop antibody-based immunotherapies for cancer. Its antibody-discovery focus and oncology pipeline make it an emerging comparable in the antibody therapeutics space.

TypeDirect peer
Description

Day One Biopharmaceuticals develops targeted therapies for pediatric oncology and rare diseases of childhood. Its pediatric cancer focus and specialty pharma structure make it a directly comparable peer for Renaissance's pediatric neuroblastoma indication.

TypeDirect peer
Description

United Therapeutics markets Unituxin (dinutuximab), the first FDA-approved anti-GD2 antibody for high-risk neuroblastoma. As the established incumbent in Renaissance's target indication, it represents the primary competitive benchmark for efficacy, safety, and market access.

TypeBroad incumbent
Description

MacroGenics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based therapeutics for cancer. While not focused on neuroblastoma specifically, its antibody platform and oncology pipeline make it a comparable peer in the anti-GD2/biologics space.

TypeBroad incumbent
Description

AstraZeneca is a major pharmaceutical company with significant oncology and rare disease franchises. Its broad biopharmaceutical portfolio, including antibody therapeutics, makes it a relevant comparable as a potential acquirer or competitor in the oncology biologics space.

TypeBroad incumbent
Description

Roche/Genentech is a global biopharmaceutical leader with extensive oncology and rare disease pipelines, including antibody-based biologics. Its scale and pediatric oncology experience make it a relevant broad incumbent peer.

TypeEmerging player
Description

Phanes Therapeutics is a clinical-stage biopharmaceutical company developing biologics for oncology and eye diseases. Its emerging pipeline of antibody-based oncology therapeutics makes it a comparable emerging player in the biologics development space.

TypeRegional player
Description

Innovent Biologics is a Chinese biopharmaceutical company developing monoclonal antibody therapeutics for oncology. Renaissance's exclusive license includes China rights, and Innovent's presence in the Chinese oncology biologics market makes it a regionally relevant peer.

TypeEmerging player
Description

Eureka Therapeutics is a clinical-stage company developing T-cell receptor-based therapies and antibodies for solid tumors including neuroblastoma. Its work on anti-GD2 CAR-T and antibody approaches overlaps with Renaissance's anti-GD2 strategy.

TypeDirect peer
Description

Y-mAbs developed and commercializes Danyelza (naxitamab), an approved anti-GD2 monoclonal antibody for high-risk neuroblastoma. It is the most directly comparable competitor to Renaissance Pharma, operating in the same indication with the same target and mechanism.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Renaissance Pharma

Pediatric Oncology Biopharmaceuticalsrenaissancepharma.co.uk

Renaissance Pharma is a clinical-stage pharmaceutical company developing Daretabart, a humanised anti-GD2 monoclonal antibody immunotherapy for high-risk neuroblastoma in paediatric patients, operating as a wholly owned subsidiary of Essential Pharma.

What Renaissance Pharma does

Renaissance Pharma Ltd is a clinical-stage pharmaceutical company developing Daretabart (hu14.18K322A), a humanised anti-GD2 monoclonal antibody immunotherapy for the treatment of high-risk neuroblastoma (HRNB), a rare paediatric cancer with only a 50% five-year survival rate under current multimodal standard of care. Founded in 2023 in Manchester, UK by Executive Chairman Lee Morley and CEO Simon Ball, the company in-licensed Daretabart exclusively from St. Jude Children's Research Hospital in August 2023, securing development, manufacturing and commercialisation rights across the US, Canada, Europe, China, Japan and Turkey.

The technical core is a humanised anti-GD2 antibody engineered with three differentiating features: 98% human composition, a specialised cell line producing lower antibody glycosylation, and a K322A mutation designed to limit complement activation and improve tolerability versus earlier-generation anti-GD2 antibodies. Phase II clinical data demonstrated an 86.0% overall survival rate at three years and a 73.7% event-free survival rate in newly diagnosed HRNB patients, with 96.8% achieving partial response or better at the end of induction. In April 2026, the FDA granted Fast Track Designation and IND clearance, enabling initiation of the SHINE Phase II/III trial, and the first commercial-scale GMP batch was successfully manufactured.

Renaissance Pharma is pre-revenue; the disclosed revenue model is pharmaceutical product sales of Daretabart upon regulatory approval. The company was acquired in March 2024 by Essential Pharma, an international specialty pharma group focused on niche, clinically differentiated products, and now operates as a wholly owned subsidiary. Leadership comprises CEO Simon Ball (also Interim CEO of Essential Pharma), Executive Chairman Lee Morley, CMO Dr. Jonathan Morgan and CTO Debra Nevin, with engagement of FDA, EMA and other regulators to configure the optimal submission and commercialisation path.

Renaissance Pharma firmographics

Firmographics
Name
Renaissance Pharma
Legal name
Renaissance Pharma Ltd
Website
https://renaissancepharma.co.uk
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Renaissance Pharma is a clinical-stage pharmaceutical company developing Daretabart, a humanised anti-GD2 monoclonal antibody immunotherapy for high-risk neuroblastoma in paediatric patients, operating as a wholly owned subsidiary of Essential Pharma.
Ownership category
akta.pro rank

Renaissance Pharma industry classification

Industry
Product category
Pediatric Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Pediatric oncology therapeutics
  • Monoclonal antibody immunotherapy
  • Rare disease drug development
  • Anti-GD2 antibody treatment
  • Neuroblastoma clinical development

Where Renaissance Pharma is headquartered

Location

Headquarters

HQ city
Manchester
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Renaissance Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical product sales: Pre-revenue development stage company. Revenue will be generated through commercialization of Daretabart (hu14.18K322A) upon regulatory approval for the treatment of high-risk neuroblastoma.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Renaissance Pharma product offering

Product offering

Core offering

Renaissance Pharma is a clinical-stage pharmaceutical company developing Daretabart (hu14.18K322A), a humanized anti-GD2 monoclonal antibody immunotherapy for the treatment of high-risk neuroblastoma in pediatric patients. The investigational compound is being evaluated in the SHINE Phase II/III trial and has received FDA Fast Track Designation and IND clearance. The asset was in-licensed from St. Jude Children's Research Hospital.

Product overview

Renaissance Pharma Limited is a single-product pharmaceutical company focused on rare pediatric diseases, specifically high-risk neuroblastoma. The company's sole offering is Daretabart (hu14.18K322A), a humanized anti-GD2 antibody immunotherapy. This investigational compound is the company's lead and only product candidate, currently in clinical development with Phase II data showing 86% overall survival rate at three years. The company operates as a subsidiary of Essential Pharma following acquisition in April 2024.

Differentiator

Problem solved

Functional benefit

Products and services

  • Daretabart (hu14.18K322A) Investigational humanized anti-GD2 monoclonal antibody immunotherapy engineered to target and destroy high-risk neuroblastoma (HRNB) cells. Specifications: 98% human composition, specialized cell line production with lower glycosylation, and a K322A mutation limiting complement activation. Phase I and II trials demonstrated tolerability and clinical activity in HRNB. In-licensed from St. Jude Children's Research Hospital.

Quantifiable outcome

  • Phase II trial: 86.0% overall survival rate at 3 years, 73.7% event-free survival rate at 3 years
  • +2 more outcomes

Companies that use Renaissance Pharma

Customer profile

Segments2 records

Ideal customer profiles1 record

Renaissance Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Renaissance Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Essential PharmacoreOthers · 22 March 2024Essential Pharma, an international specialty pharma group focused on ensuring patients have sustainable access to niche pharmaceutical products, completed acquisition of the entire issued share capital of Renaissance Pharma Ltd on March 22, 2024. This acquisition added a clinical development-stage asset to Essential Pharma's rare disease portfolio. Simon Ball, CEO and co-founder of Renaissance Pharma, continues to work with Essential Pharma on Daretabart development.
  • St. Jude Children's Research HospitalcoreOEM/ Whitelabel/ Licensing Partner · 1 August 2023Exclusive license agreement signed August 1, 2023 for Daretabart (hu14.18K322A). Renaissance Pharma secured exclusive development, manufacturing and commercialisation rights to US, Canada, Europe, China, Japan and Turkey. The antibody was originally developed by St. Jude and targets GD2 on neuroblastoma cells.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Renaissance Pharma competitors and assessment

Company assessment

Emerging players

  • Atreca: Atreca is a clinical-stage biotechnology company leveraging its immune repertoire capture technology to develop antibody-based immunotherapies for cancer. Its antibody-discovery focus and oncology pipeline make it an emerging comparable in the antibody therapeutics space.
  • Phanes Therapeutics: Phanes Therapeutics is a clinical-stage biopharmaceutical company developing biologics for oncology and eye diseases. Its emerging pipeline of antibody-based oncology therapeutics makes it a comparable emerging player in the biologics development space.
  • Eureka Therapeutics: Eureka Therapeutics is a clinical-stage company developing T-cell receptor-based therapies and antibodies for solid tumors including neuroblastoma. Its work on anti-GD2 CAR-T and antibody approaches overlaps with Renaissance's anti-GD2 strategy.

Direct peers

  • Day One Biopharmaceuticals: Day One Biopharmaceuticals develops targeted therapies for pediatric oncology and rare diseases of childhood. Its pediatric cancer focus and specialty pharma structure make it a directly comparable peer for Renaissance's pediatric neuroblastoma indication.
  • United Therapeutics: United Therapeutics markets Unituxin (dinutuximab), the first FDA-approved anti-GD2 antibody for high-risk neuroblastoma. As the established incumbent in Renaissance's target indication, it represents the primary competitive benchmark for efficacy, safety, and market access.
  • Y-mAbs Therapeutics: Y-mAbs developed and commercializes Danyelza (naxitamab), an approved anti-GD2 monoclonal antibody for high-risk neuroblastoma. It is the most directly comparable competitor to Renaissance Pharma, operating in the same indication with the same target and mechanism.

Broad incumbents

  • MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based therapeutics for cancer. While not focused on neuroblastoma specifically, its antibody platform and oncology pipeline make it a comparable peer in the anti-GD2/biologics space.
  • AstraZeneca: AstraZeneca is a major pharmaceutical company with significant oncology and rare disease franchises. Its broad biopharmaceutical portfolio, including antibody therapeutics, makes it a relevant comparable as a potential acquirer or competitor in the oncology biologics space.
  • Roche (Genentech): Roche/Genentech is a global biopharmaceutical leader with extensive oncology and rare disease pipelines, including antibody-based biologics. Its scale and pediatric oncology experience make it a relevant broad incumbent peer.

Regional players

  • Innovent Biologics: Innovent Biologics is a Chinese biopharmaceutical company developing monoclonal antibody therapeutics for oncology. Renaissance's exclusive license includes China rights, and Innovent's presence in the Chinese oncology biologics market makes it a regionally relevant peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Renaissance Pharma social profiles

Digital presence

Renaissance Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Renaissance Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Renaissance Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Renaissance Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renaissance Pharma

What does Renaissance Pharma do?

Renaissance Pharma is a clinical-stage pharmaceutical company developing Daretabart (hu14.18K322A), a humanized anti-GD2 monoclonal antibody immunotherapy for the treatment of high-risk neuroblastoma in pediatric patients. The investigational compound is being evaluated in the SHINE Phase II/III trial and has received FDA Fast Track Designation and IND clearance. The asset was in-licensed from St. Jude Children's Research Hospital.

Is Renaissance Pharma a public or private company?

Renaissance Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Renaissance Pharma founded?

Renaissance Pharma was founded in 2023. It employs 1 to 10 people.

Where is Renaissance Pharma based?

Renaissance Pharma is headquartered in Manchester, United Kingdom, in the Europe region.

How does Renaissance Pharma make money?

One revenue line is on record: pharmaceutical product sales.

Who are Renaissance Pharma's main competitors?

Emerging players on record are Atreca, Phanes Therapeutics and Eureka Therapeutics. Direct peers are Day One Biopharmaceuticals, United Therapeutics and Y-mAbs Therapeutics. Broad incumbents are MacroGenics, AstraZeneca and Roche (Genentech). Innovent Biologics is listed as a regional player.

Does Renaissance Pharma have an API?

No public API is recorded for Renaissance Pharma.

What industry is Renaissance Pharma in?

Renaissance Pharma's product category is Pediatric Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialFOR INVESTORS AND FINANCIAL AND BUSINESS MEDIA ONLY Renaissance Pharma Secures FDA Breakthrough Therapy Designation For Daretabart In Newly Diagnosed High-Risk NeuroblastomaRenaissance Pharma announced the FDA granted Breakthrough Therapy Designation for daretabart in combination with induction chemotherapy for first-line treatment of newly diagnosed high-risk neuroblastoma in pediatric patients. The designation follows Phase II data showing 73.7% three-year event-free survival and 86.0% overall survival. The company plans to execute its clinical development strategy, including the ongoing SHINE study and a future induction study.GlobeNewswireFOR INVESTORS AND FINANCIAL AND BUSINESS MEDIA ONLY Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastomaRenaissance Pharma announced the FDA granted Breakthrough Therapy Designation for daretabart in combination with induction chemotherapy for first-line treatment of newly diagnosed high-risk neuroblastoma in pediatric patients. The designation follows Phase II data showing 73.7% three-year event-free survival and 86.0% overall survival. The company plans to execute its clinical development strategy, including the ongoing SHINE study and a future induction study.PharmaTimesAragen to manufacture Renaissance Pharma’s FDA Fast Track mAbAragen completed technology transfer and first commercial-scale GMP runs for Renaissance Pharma's anti-GD2 antibody Daretabart, which received FDA Fast Track Designation in April 2026. The Bengaluru facility can produce 60-70 batches annually at 2KL scale, supporting clinical and commercial supply.GlobeNewswireRenaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastomaFDA granted Fast Track Designation and IND clearance for Daretabart (hu1418K322A), enabling the SHINE Phase II/III trial in relapse or refractory high-risk neuroblastoma. The first commercial-scale GMP batch was manufactured, building on Phase II data showing 86% overall survival. The company expects to share trial data as the study progresses.GlobeNewswireRenaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastomaRenaissance Pharma Limited, an Essential Pharma subsidiary, has received FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A), enabling initiation of the SHINE Phase II/III clinical trial for high-risk neuroblastoma in pediatric patients. The company also successfully manufactured its first commercial-scale GMP batch of the drug, marking a key operational milestone as the programme advances toward potential commercialization. The antibody, targeting GD2 on neuroblastoma cells, builds on Phase II data showing an 86% overall survival rate at three years.BioSpaceRenaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastomaFDA granted Fast Track designation and IND clearance for Daretabart (hu1418K322A), enabling the SHINE Phase II/III trial in relapse or refractory high-risk neuroblastoma. The first commercial-scale GMP batch was manufactured, building on Phase II data showing 86% overall survival. The company expects to share trial data as the study progresses.GlobeNewswireEssential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastomaEssential Pharma completed the acquisition of Renaissance Pharma, adding its Phase II immunotherapy Hu14.18 for high-risk neuroblastoma. The drug showed 73.7% event-free survival and 86% overall survival in a Phase II trial. Essential Pharma will drive development and commercialization.GlobeNewswireEssential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastomaEssential Pharma has completed the acquisition of Renaissance Pharma Ltd, adding its clinical-stage immunotherapy Hu14.18 for high-risk neuroblastoma to its portfolio. This transaction marks Essential Pharma's first development-stage asset and aims to address significant unmet needs in paediatric oncology through continued clinical development and eventual commercial launch.YahooEssential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastomaEssential Pharma has completed the acquisition of Renaissance Pharma Ltd, adding its clinical-stage immunotherapy Hu14.18K322A for high-risk neuroblastoma to its portfolio. This transaction marks Essential Pharma's first clinical development-stage asset and supports its strategy of targeting unmet needs in rare paediatric diseases. The lead asset has shown positive outcomes in Phase II trials, with data published in the Journal of Clinical Oncology indicating improved survival rates.European BiotechnologyEssential Pharma acquires Renaissance Pharma LtdEssential Pharma Group has acquired Renaissance Pharma Ltd, securing rights to the Phase II candidate Hu14.18K322A for treating high-risk neuroblastoma in children. This acquisition adds a clinical-stage asset to Essential Pharma’s rare disease portfolio and leverages the drug's strong Phase II survival rates of 73.7% event-free and 86% overall. The deal includes the continuation of Renaissance Pharma’s team, led by CEO Simon Ball, in the further development of the therapy.